Crispr Therapeutics Ag - Common Shares (CRSP) closed at $50.07 on November 6, 2026, up 3.1% from the previous close, on volume of 1,115,189 shares (30-day average 1,387,533).
Data as of November 6, 2026.
Crispr Therapeutics Updates CTX131 Cancer Trial: What Investors Need to Know
TipRanks (Thu, 5-Nov 11:30 AM ET)
Market Chameleon (Wed, 4-Nov 4:36 AM ET)
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
TipRanks (Wed, 4-Nov 8:30 AM ET)
TipRanks (Wed, 4-Nov 5:10 AM ET)
Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital
TipRanks (Tue, 3-Nov 8:45 PM ET)
Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)
TipRanks (Tue, 3-Nov 1:30 PM ET)
Crispr Therapeutics AG (CRSP) Receives a Rating Update from a Top Analyst
TipRanks (Tue, 3-Nov 8:04 AM ET)
Crispr Therapeutics AG (CRSP) Receives a Buy from Piper Sandler
TipRanks (Tue, 3-Nov 7:56 AM ET)
CRISPR Therapeutics’ Growing Casgevy Adoption and Near-Term Pipeline Catalysts Support a Buy Rating
TipRanks (Tue, 3-Nov 7:47 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of November 6, 2026, CRSP stock price climbed to $50.07 with 1,115,189 million shares trading.
CRSP has a beta of 2.04, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.19 to the broad based SPY ETF.
CRSP has a market cap of $4.84 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $13 million in Revenue and -$1.15 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.09.
In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKE, ARKK, XBI, IWM, ARKG.
CRSP has underperformed the market in the last year with a return of -12.1%, while the SPY ETF gained +9.6%. In the last 3 month period, CRSP fell short of the market, returning -4.5%, while SPY returned -4.2%. However, in the most recent 2 weeks CRSP has outperformed the stock market by returning +0.2%, while SPY returned -3.8%.
CRSP support price is $46.74 and resistance is $50.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.
